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Background. The coronary heart disease (CHD) risk locus on 21q22 (lead SNP rs9982601) lies within a “gene desert.” The aim
of this study was to assess if this locus is associated with CHD risk factors and to identify the functional variant(s) and gene(s)
involved. Methods. A phenome scan was performed with UCLEB Consortium data. Allele-specific protein binding was studied
using electrophoretic mobility shift assays. Dual-reporter luciferase assays were used to assess the impact of genetic variation on
expression. Expression quantitative trait analysis was performed with Advanced Study of Aortic Pathology (ASAP) and Genotype-
Tissue Expression (GTEx) consortium data. Results. A suggestive association between QT interval and the locus was observed
(rs9982601 𝑝 = 0.04). One variant at the locus, rs28451064, showed allele-specific protein binding and its minor allele showed
12% higher luciferase expression (𝑝 = 4.82 × 10−3) compared to the common allele. The minor allele of rs9982601 was associated
with higher expression of the closest upstream genes (SLC5A3 1.30-fold increase 𝑝 = 3.98 × 10−5;MRPS6 1.15-fold increase 𝑝 = 9.60
× 10−4) in aortic intima media in ASAP. Both rs9982601 and rs28451064 showed a suggestive association withMRPS6 expression
in relevant tissues in the GTEx data. Conclusions. A candidate functional variant, rs28451064, was identified. Future work should
focus on identifying the pathway(s) involved.
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1. Introduction
Thecoronary heart disease (CHD) risk locus on chromosome
21q22 (lead SNP, rs9982601) is typical of many variants
associated with common disease in genome-wide association
studies (GWAS) in that the locus falls in an intergenic region
and is not associated with any major CHD risk factors [1]. As
such, there is no obvious mechanism through which it is
affecting CHD risk. Neither the lead SNP at the 21q22 risk
locus nor any SNPs in strong linkage disequilibrium (LD)
with it result in changes to the protein coding sequence or
splice sites in any of the nearby genes. Therefore, the locus
does not influence CHD risk by altering protein composition
or structure. Rather, it is likely that the locus elicits its effect
through involvement in the regulation of gene expression [2].
A feature of the GWAS methodology is that a prior hypoth-
esis of which loci are influencing a trait or disease is not
required. Therefore, it has the potential to identify risk
variants and ultimately molecular pathways which otherwise
would remain obscure. However, to fully take advantage of
this, functional analysis of GWAS loci is required to deter-
mine the mechanism(s) involved.
The closest downstream gene to the risk locus is the
potassium channel subunit encoding KCNE2. Mutations in
this protein are known to cause long-QT syndrome [3], which
is associatedwith arrhythmias and sudden cardiac death. Fur-
thermore, even within the normal range, longer QT interval
has been associated with increased risk of CHD mortality
[4], although it is unclear whether the association is a causal
relationship. Upstream of the risk locus, the closest genes are
SLC5A3 and MRSP6. These genes share an exon which is
in the open reading frame for MRPS6 but not SLC5A3 [5].
SLC5A3 (solute carrier family 5-inositol transporter) encodes
a sodium myoinositol transporter which is involved in the
response to hyperosmotic stress [6]. MRPS6 (mitochondrial
ribosomal protein 6) encodes a subunit of the mitochondrial
ribosome [7]. The lead SNP at this locus, rs9982601, has
been found to be associated with expression of MRPS6 in
blood, with the risk allele showing increased expression [8],
indicating that risk locus might be involved in regulating the
expression of this gene. However, none of these genes point
to a plausible pathway to account for the association with
CHDand thus genomic location does not suggest any obvious
mechanism through which this CHD risk locus is acting.
As part of our ongoing functional analysis of GWAS-
identified CHD risk loci we sought to investigate the mech-
anism through which the 21q22 risk locus influences CHD
risk. The aims of this study were firstly to assess whether the
risk locus was associated with any traits that may give insight
into the mechanism through which the locus affects risk by
performing a phenome scan using data from the University
College, London School of Hygiene and Tropical Medicine,
Edinburgh and Bristol (UCLEB) Consortium of large-scale
cohort studies. Secondly, we sought to identify candidate
functional SNP(s) using in vitro assays and thirdly to assess
relationship between the risk locus and gene expression by
performing expression quantitative trait loci (eQTL) analysis
with data from the Advanced Study of Aortic Pathology
(ASAP) and theGenotype-Tissue Expression (GTEx) consor-
tium.
2. Methods
2.1. Phenome Scan. TheUniversityCollege, London School of
Hygiene and Tropical Medicine, Edinburgh and Bristol
(UCLEB) Consortium comprises 12 prospective studies and
has been described in detail elsewhere [9]. Approximately
21,000 participants included in the UCLEB studies were
genotyped using the Metabochip [10]. This platform has
approximately 200,000 SNPs, designed to cover regions asso-
ciated with cardiometabolic disease. Traits available included
a number of physiological phenotypes, lipid measures, and
inflammatorymarkers. Informed consentwas obtained for all
subjects included in UCLEB research. Written approval from
individual Research Ethics Committees to use anonymised
individual level data has been obtained by each participating
study.
2.2. Bioinformatics. HaploReg v2 [11]was used to characterise
the lead SNP at the risk locus and those in strong LD with it.
LD data came from the 1000 Genomes Project phase 1. The
annotations displayed include chromatin state assignments
from the ENCODE project [12] and the Roadmap Epige-
nomics Consortium [13] as well as DNA hypersensitivity site
and protein binding annotations from the ENCODE project.
Predicted changes in transcription factor binding were
assessed using the Genomatix Software Suite (Genomatix
Software GmbH, Munich, Germany).
2.3. Electrophoretic Mobility Shift Assay (EMSA). Hepato-
cellular carcinoma cell lines (Huh-7 and HepG2) were
obtained from the European Collection of Cell Cultures.
The cells were cultured and nuclear proteins extracted as
described in [14]. Probes with 25 bases flanking the SNP
of interest were designed (two per SNP, one for each
allele), biotinylated, and annealed to form double stranded
oligonucleotides. Probe sequences are given in Supplemen-
tary Table 1, in Supplementary Material available online at
https://doi.org/10.1155/2017/1096916. The probes were incu-
bated with nuclear extract (with or without competitor) at
25∘C for 50minutes. Following this the reactions were run on
a 6% polyacrylamide gel for 210 minutes at 120V and
thereafter transferred on to Hybond-N+ membrane using
Southern transfer [15]. DNA-protein complexes were cross-
linked to themembrane and visualised and using theThermo
Scientific Lightshift Chemiluminescent Nucleic Acid Detec-
tion Module (according to the manufacturer’s instructions,
Thermo Fisher Scientific, Waltham, MA, USA).
2.4. Dual-Reporter Luciferase Assay. The region surrounding
the putative functional SNP was cloned into the pGL3 pro-
moter vector (Promega, Madison, WI, USA) at the enhancer
region using the SalI/BamHI restriction sites. Huh-7 cells
were seeded 1–5 × 10−4 cells/well and grown to near conflu-
ence. The cells were then transfected using Lipofectamine
(Invitrogen, Life Technologies, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions and left for 48 hours.
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Table 1: The association between four SNPs at the CHD risk locus on chromosome 21q22 and mean QT interval in UCLEB.
SNP Beta coefficient 𝑝 value
rs9982601
Genotype CC TC TT
1.83 (0.90) 0.04𝑛 (frequency) 5329 (0.75) 1643 (0.23) 130 (0.02)
Mean QT interval (ms) 402.8 (37.35) 404.5 (39.28) 409.1 (41.08)
rs8131284
Genotype TT CT CC
2.14 (0.89) 0.02𝑛 (frequency) 5293 (0.75) 1670 (0.24) 142 (0.02)
Mean QT interval (ms) 402.7 (37.41) 404.9 (39.20) 408.1 (38.97)
rs7278204
Genotype AA GA GG
2.07 (0.89) 0.02𝑛 (frequency) 5290 (0.74) 1673 (0.24) 141 (0.02)
Mean QT interval (ms) 402.7 (37.73) 404.9 (38.19) 407.9 (39.26)
rs973754
Genotype AA GA GG
1.85 (0.89) 0.02𝑛 (frequency) 5300 (0.75) 1663 (0.23) 142 (0.02)
Mean QT interval (ms) 402.7 (37.75) 404.6 (38.18) 408.2 (38.84)
Mean QT interval is shown by genotype as well as the beta coefficient (±standard deviation) for the minor allele at each SNP.
Reporter plasmid DNA and cotransfectant DNA (pRL-TK)
were added to each well in a ratio of 200 : 1. Luciferase activity
was determined by measuring the luminescence of the cell
lysate using the TR717 Microplate Luminometer and the
Dual Luciferase assay kit (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. The ratio of
firefly luciferase readings:Renilla luciferase readingswas then
compared between the different constructs using paired 𝑡-
tests. Four runs of eleven or twelve replicates were performed.
2.5. eQTL Analysis
2.5.1. ASAP. Patients undergoing aortic value surgery at the
Karolinska University Hospital, Stockholm, Sweden, were
recruited (𝑛 = 213) into ASAP [16]. Tissue biopsies were
taken from the mammary artery, aortic adventitia, aortic
intimamedia, heart, and liver. Messenger RNAwas extracted
and measured using the Affymetrix Gene Chip Human Exon
1.0 ST Expression Array (Santa Clara, CA, USA). Genotyping
was performed using the Illumina Human 610W Quad
Beadarrays (San Diego, CA, USA). All participants gave
informed consent and the study had approval from the ethical
committee of the Karolinska Institute. The ASAP data was
used to assess the relationship between the risk locus and the
closest upstream and downstream genes—SLC5A3, MRPS6,
and KCNE2—in the five available tissues.
2.5.2. GTEx. The GTEx consortium seeks to provide a re-
source to study the relationship between genetic variation and
gene expression by collecting multiple samples from densely
genotypes donors [17]. The data is publically available on the
GTEx browser (http://gtexportal.org/home/).TheGTEx data
was used to assess the relationships between SNPs at the risk
locus withMRPS6 andKCNE2 expression in the aortic artery,
coronary artery, tibial artery, atrial appendage, left ventricle
liver, and whole blood.
3. Results
3.1. Association of the 21q22 CHD Risk Locus with CHD Risk
Factors. A phenome scan of the UCLEB Consortium data
was performed to determine if SNPs at the 21q22 risk locus
were associated with risk factors for CHD. Four SNPs at the
21q22 locus were analysed, the lead SNP rs9982601 and
three SNPs in moderate LD with it, rs8131284 (𝑟2 = 0.78),
rs7278204 (𝑟2 = 0.76), and rs973754 (𝑟2 = 0.75). Over one
hundred traits were tested (these are listed in the Appendix)
but none met the Bonferroni-adjusted significance threshold
(𝑝 = 4.72 × 10−4, based on an unadjusted significance
threshold of 𝑝 = 0.05). Only one trait, QT interval, showed a
suggestive association (𝑝 < 0.05) with the effect in the same
direction for all four SNPs (Table 1). The minor CHD risk
allele was nominally associated with longer QT interval. This
putative association is of interest due to the close proximity
of the potassium ion channel gene KCNE2 to the risk locus.
3.2. Identification of a Putative Functional SNP
3.2.1. Bioinformatics Analysis of the CHD Risk Locus 21q22.
Five SNPs in strong LD (𝑟2 > 0.8) with the lead SNP
rs9982601 were identified using HaploReg v2 [11]. Only one
SNP (rs28451064) resided within an enhancer region (in
the liver cell line HepG2). This SNP was also found to be
positioned within a site bound by multiple transcription
factors including specificity protein 1 (SP1) and forkhead box
A2 (FOXA2), also in HepG2 cells.
3.2.2. Assessment of Allele-Specific Binding. EMSAs were
performed for the lead SNP and the five in strong LD with it,
to assess if any of the SNPs showed allele-specific binding.
The assays were carried out with nuclear extracts from two
hepatocyte carcinoma cell lines, HepG2 and Huh-7, as the
only enhancer chromatin marks found for any of the SNPs
at this locus were in HepG2 cells. Only rs28451064 showed
consistent allele-specific binding (Figure 1). Therefore, the
result of the EMSAs together with the bioinformatics analysis
identifies rs28451064 as a strong candidate to be the func-
tional SNP.
3.2.3. Impact of rs28451064 on Transcription Factor Bind-
ing. To assess whether transcription factor binding may be
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Figure 1: Replication of EMSAs with (a) rs60687299, (b) rs977419, (c) rs977093, (d) rs9982601, and (e) rs28451064 probes using HepG2 and
Huh-7 nuclear extract. Binding by both alleles was compared for all five SNPs. Only in (e) (rs28451064) is there strong binding for one allele
but complete absence of binding for the other in both cell lines.
affected by the presence of different alleles at rs28451064, the
Genomatix Software Suite (Genomatix Software GmbH,
Munich, Germany) was used. Presence of the minor “A”
allele rather than the major “G” allele was predicted to
abolish a vitaminD receptor-retinoidX receptor (VDR-RXR)
heterodimer binding site and a homeodomain protein H6
familymember 3 (HMX3) binding site.The software also pre-
dicted the creation of a forkhead-related transcription factor
4 (FREAC4) binding site in the presence of the (minor) A
allele.
To investigate whether VDR or RXR were binding to
the rs28451064 probes in vitro, competitor EMSAs were
performed with both Huh-7 and HepG2 nuclear extracts.
SP1 and FOXA2 were also investigated as these proteins had
been found to bind at this locus in the HepG2 cell line in
the ENCODE project (Figure 2). SP1 binding to its consensus
sequence was not competed out by the addition of the
rs28451064-G probe and the RXR consensus probe did not
bind proteins in either extract, demonstrating that these were
unlikely to be the bound factor. There were no consistent
binding results with FOXA2 and VDR, and thus no firm
conclusions on their binding to rs28451064 in vitro could be
drawn.
3.2.4. Impact of rs28451064 on Reporter Gene Expression. The
impact of rs28451064 on gene expression was assessed using
a luciferase dual-reporter assay. To do this, a fragment of
300 bp containing the SNP was cloned into the enhancer site
of the pGL3 promoter vector and the plasmids transfected
into Huh-7 cells. Figure 3 shows the relative expression of the
reporter gene containing the rs28451064 insert compared to
the pGL3 promoter plasmid. Both rs28451064 plasmids
showed higher expression (A allele 87% higher 𝑝 = 1.90 ×
10−15, G allele 62% higher 𝑝 = 9.74 × 10−15) than the pGL3
promoter plasmid, suggesting that this region acts as an
enhancer. Moreover, in agreement with the eQTL data pre-
sented below, the minor A (risk) allele was found to have 12%
higher expression compared to the G allele (𝑝 = 4.82 × 10−3).
3.3. eQTL Analysis. The relationship between the lead SNP
at the risk locus and expression of its three closest genes
MRPS6, SLC5A3, and KCNE2 was examined using data from
the ASAP study [16]. Expression levels in five tissues (liver,
mammary artery, aortic adventitia, aortic intima media, and
heart) and rs9982601 genotype data was available for 106
ASAP participants.Theminor CHD risk allele was associated
with higher expression of the mRNA transcript in aortic
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Figure 2: Competitor EMSA results from assays performed with (a) SP1 probes, (b) VDR probes, (c) RXR probes, and (d) FOXA2 probes
and HepG2 and Huh-7 nuclear extracts. ∗G allele of rs28451064.
intimamedia for both SLC5A3 andMRPS6 (SLC5A3 1.30-fold
(95% CIs 1.16–1.47) per A allele 𝑝 = 3.98 × 10−5; MRPS6
1.15-fold (95% CIs 1.06–1.25) per A allele 𝑝 = 9.60 × 10−4,
Figure 4). However, no association was observed for KCNE2.
Similar results were observed for rs28451064 (SLC5A3 1.40-
fold increase per minor allele, 𝑝 = 1.08 × 10−6; MRPS6 1.20-
fold increase per minor allele, 𝑝 = 1.47 × 10−5).
The relationship between the 21q22 CHD risk locus and
gene expressionwas further studied using publically available
data from the GTEx project (http://www.gtexportal.org/)
[17]. No genes met the significance threshold for a single
tissue eQTL with either the lead SNP rs9982601 or the
putative functional SNP rs28451064. The search was then
narrowed to consider the relationship between the risk locus
and the three genes located most closely to it, KCNE2,
MRPS6, and SLC5A3, in seven relevant tissues (Table 2). This
gives a Bonferroni-adjusted p value of 4 × 10−3 (based on an
unadjusted significance threshold of 𝑝 = 0.05). In agreement
with the ASAP results, the minor allele of rs9982601 was
found to be associated with higher expression of MRPS6 in
the aortic (effect of minor allele relative to common allele =
0.15, 𝑝 = 3.5 × 10−3) and tibial arteries (effect of minor allele
relative to common allele = 0.15, 𝑝 = 1.8 × 10−4), although not
in the coronary artery. There was a suggestive association
between the minor allele and lower expression of MRPS6
in whole blood (effect of minor allele relative to common
allele = −0.09, 𝑝 = 0.04). There were suggestive associations
between the minor allele of rs9982601 and higher expression
of KCEN2 in aortic and tibial artery tissue (effect of minor
allele relative to common allele = 0.13, 𝑝 = 0.06, and
effect of minor allele relative to common allele = 0.15,
𝑝 = 0.02, resp.). Expression data for SLC5A3 was not
available. Results for rs28451064 were very similar (data not
shown).
4. Discussion
The locus on chromosome 21q22 has been consistently asso-
ciated with CHD, with odds ratio of 1.13 per minor allele in
the CARDIoGRAMplusC4Dmeta-analysis [1], which is rela-
tively high for a GWAS-identified risk variant. However, like
the majority of the confirmed GWAS loci for CHD, there
is no obvious functional mechanism through which the
locus influences CHD risk [1]. In this study, rs28451064 was
identified as a putative functional SNP at the locus.Theminor
CHDrisk allele was found to show less protein binding and be
associatedwith higher gene expression in vitro.This allelewas
also found to be associated with higher expression of the two
closest upstream genes (MRPS6 and SLC5A3) in a number of
tissues. In agreement with previous studies, no significant
association between the lead SNP, rs9982601, and risk factors
for CHD was observed. A suggestive association between
the risk locus and QT interval was observed, indicating
that it may be affecting CHD risk through regulating the
expression of the potassium channel subunit gene KCNE2,
the closest downstream gene to the risk locus. However, while
a suggestive association between rs9982601 and KCNE2
expression in the aortic and tibial arteries was observed in
the GTEx data, the evidence for the risk locus being involved
in the regulation ofMRPS6 and SLC5A3wasmore consistent.
These data raise the possibility that the risk locus is acting on
more than one pathway influencing the development of CHD.
While a putative functional SNP was identified, the
transcription factors involved remain to be identified. The
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Table 2: Relationship between rs9982601 and expression of selected genes in seven tissues from GTEx (http://www.gtexportal.org/home/).
Gene Tissue 𝑛 Effect size (se) 𝑝 value
MRPS6 Aortic artery 197 0.15 (0.05) 3.5 × 10−3
MRPS6 Coronary artery 118 0.14 (0.11) 0.22
MRPS6 Tibial artery 285 0.15 (0.05) 1.8 × 10−3
MRPS6 Atrial appendage 159 −0.02 (0.09) 0.88
MRPS6 Left ventricle (heart) 190 −0.16 (0.10) 0.09
MRPS6 Liver 97 −0.19 (0.14) 0.17
MRPS6 Whole blood 338 −0.09 (0.04) 0.04
KCNE2 Aortic artery 197 0.13 (0.07) 0.06
KCNE2 Coronary artery 118 0.09 (0.11) 0.43
KCNE2 Tibial artery 285 0.15 (0.06) 0.02
KCNE2 Atrial appendage 159 0.13 (0.16) 0.41
KCNE2 Left ventricle (heart) 190 −0.06 (0.14) 0.71
KCNE2 Liver 97 0.05 (0.15) 0.31
KCNE2 Whole blood 338 8.40 × 10−3 (0.15) 0.92
Effect sizes refer to the effect of the minor allele on expression relative to the common allele. se = standard error.
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Figure 3: Relative expression of a vector containing the rs284510654
A allele and rs28451064 G allele normalised to the pGL3 promoter
expression. Relative expression was compared using paired 𝑡-tests.
Both plasmids containing the sequence surrounding rs28451064
showed higher expression (A allele 87% higher 𝑝 = 1.90 × 10−15, G
allele 62% higher 𝑝 = 9.74 × 10−15). The A allele was found to have
12% higher expression compared to the G allele (𝑝 = 4.82 × 10−3).
minor (risk) allele of rs28451064 was predicted to abolish
a binding site for the VDR-RXR heterodimer transcription
factor complex. A large-scale analysis performed in lym-
phoblastoid cells found that expression of both MRPS6 and
SLC5A3 increased in response to treatment with calcitriol
(a bioactive form of vitamin D) [18]. This suggests that the
VDR pathway is involved in expression of these two genes,
SLC5A3
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Figure 4: Expression of (a) SLC5A3 and (b)MRPS6 in aortic intima
media presented by rs9982601 genotype in the ASAP study. The
minor allele of rs9982601 was associated with higher expression of
both SLC5A3 (1.30-fold (95% CIs 1.16–1.47) per A allele 𝑝 = 3.98 ×
10−5) andMRPS6 (1.15-fold (95% CIs 1.06–1.25) per A allele 𝑝 = 9.60
× 10−4).
although if so, it is not a simple relationship given that higher
expression of both genes is associated with the minor (risk)
allele which is also predicted to abolish the VDR binding
site. The competitor EMSAs performed herein investigated
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which transcription factors were binding the rs28451064-
G probe; however the results were inconsistent and VDR
binding to the probe could neither be confirmed nor be
refuted.
How increased expression of any of the nearby genes
(MRPS6, SLC53, and KCNE2) might affect CHD risk is
unclear. As a constituent part of the mitochondrial ribosome,
the gene product of MRPS6 plays a key role in the syn-
thesis of the thirteen proteins encoded in mitochondrial
DNA, all of which are involved in oxidative phosphorylation
[19]. An important by-product of oxidative phosphorylation
is the generation of reactive oxygen species (ROS) [20].
Overproduction of ROS by dysfunctional mitochondria has
been associated with multiple proatherogenic consequences
including the activation of inflammatory pathways and
endothelial dysfunction, but whether this is a causal rela-
tionship remains to be determined [21]. If so, it may be that
increased expression of MRPS6 caused by presence of the
risk allele disrupts the translation of the genes encoded by
themitochondrial DNA, increasing the risk of mitochondrial
dysfunction and ultimately oxidative stress.
The sequence of SLC5A3 lies completely within that
of MRPS6. The protein encoded by SLC5A3 is a sodium-
myoinositol cotransporter (SLC5A3). This transporter plays
an important role in the maintenance of cell volume in
response to hyperosmotic stress. As osmolarity of the extra-
cellular fluid increases, nonselective cation channels are
activated causing sodium ions to enter the cell, disrupting
cellular ion homeostasis. In response, solute carrier family
proteins (including SLC5A3) are activated causing increased
transport of small organic molecules such as myoinositol,
referred to as “compatible osmolytes” to replace inorganic
ions [22]. Recent evidence has suggested that SLC5A3 is
also involved in the response to hypotonic stress but this is
much less well understood [23]. Work in mouse models has
found that SLC5A3 is involved in the development of the
peripheral nervous system and respiratory gas exchange [24,
25]. From current knowledge there is no obvious mechanism
to link SLC5A3 with the pathogenesis of CHD. However,
as there may be a number of pathways which contribute
to atherosclerosis yet to be elucidated (indicated by the
number of GWAS hits with unknown mechanisms), the
involvement of SLC5A3 cannot be discounted. Alternatively,
the association between the risk locus and expression of this
genemay simply be a consequence of its sharing an exon with
MRPS6 [5].
The relationship between KCNE2 and CHD appears to be
complex. The ion channel subunit encoded by KCNE2 has
a long established relationship with QT interval (and thus
with the electrical activity of the ventricles). How this
may relate to CHD risk is yet to be determined. Recently,
deletion of the gene was found to promote spontaneous
atherosclerotic lesions in mice [26]. These mice also had
raised LDL-cholesterol and impaired glucose tolerance, both
proatherogenic characteristics [27]. While results from mice
are not directly translatable to humans, this does provide
preliminary evidence of a causal relationship betweenKCNE2
and CHD. However, only weak evidence for a relationship
between the 21q22 risk locus and the gene was observed in
this study.
This work has a number of limitations. Functional molec-
ular assays were performed in hepatocyte carcinoma cell lines
and these may not be the most appropriate cellular model.
However, the putative functional SNP, rs28451064, was found
to have enhancer chromatin marks in HepG2 (hepatocyte)
cells and lie in both a DNAse I hypersensitivity site and
transcription binding sites. This indicates that the SNP lies in
open chromatin in this cell line and thus may be influencing
gene expression. Furthermore, since the mechanism through
which this locus impacts upon risk remains obscure, it is not
clear which cell type would serve as the most appropriate
model. The luciferase assays were performed using the pGL3
promoter vector which contains a general SV40 bacterial pro-
moter. It would have been preferable to use the promoter of
either MRPS6 or SLC5A3. However, the MRPS6 promoter is
not well characterised and attempts to clone the SLC5A3
promoter sequence into the pGL3 basic plasmid were unsuc-
cessful. A further limitation is that the in vitro assays per-
formed herein are unable to take account of chromatin state
or to assess long distance interactions. However, chromatin
capture techniques are now in mainstream use which can
overcome this issue. The methods can be used to investigate
whether two loci interact (chromatin conformation capture,
3C [28]) or to identify interaction partners for a particular
locus circular chromosome confirmation capture [29]. Future
work on this locus should focus on this.
In conclusion, functional analysis of the 21q22 CHD risk
locus was performed, identifying a putative functional SNP,
rs28451064. However, the affected gene(s) and transcription
factor(s) remain obscure. Future work should focus on iden-
tifying the pathway(s) through which this locus influences
CHD risk, specifically the transcription factors and genomic
loci involved.
Appendix
The traits included in the phenome scan were as follows:
albumin, alcohol use, alkaline phosphate, alanine transami-
nase, apoa1, apob, activated partial thromboplastin time,
aspartate aminotransferase, basophil count, bilirubin, body
mass index, use of blood pressure lowering medication, elec-
trocardiogram cornell product, creatinine, C-reactive pro-
tein, diastolic blood pressure, D-dimer, estimated glomerular
filtration rate, eosinophil count, factor VII, factor VIII,
ferritin, forced expiatory volume in 1 second, fibrinogen,
forced vital capacity, gamma-glutamyl transpeptidase, glu-
cose, use of glucose lowering drugs, haemoglobin, glyca-
ted haemoglobin, haematocrit, homocysteine, high density
lipoprotein cholesterol, height, insulin-like growth factor-1,
interleukin-6, insulin, low density lipoprotein cholesterol,
log(alkaline phosphate cholesterol), log(alanine transami-
nase), log(aspartate aminotransferase), log(basophil), log(bil-
irubin), log(electrocardiogram cornell product), log(C-re-
active protein), log(D-dimer), log(eosinophil count), log(fac-
tor VII), log(ferritin), log(fibrinogen), log(gamma-glutam-
yl transpeptidase), log(glucose), log(homocysteine), log(in-
terleukin-6), log(insulin), log(lipoprotein (a)), log(lympho-
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cyte count), log(monocyte count), log(electrocardiogram
QRS voltage product), log(electrocardiogram QRS voltage
sum), log(serummagnesium), log(serumphosphate), log(se-
rum urea), log(triglycerides), log(tumor necrosis factor-
alpha), log(uric acid), log(von Willebrand factor), log(white
cell count), lipoprotein (a), lymphocyte count, mean cell hae-
moglobin, mean cell volume, monocyte count, mean platelet
volume, neutrophil count, body fat percentage, peak expira-
tory flow, platelet count, PR interval, electrocardiogram QRS
voltage product, electrocardiogram QRS voltage sum, elec-
trocardiogram QT interval corrected, electrocardiogram QT
interval, red blood cell count, systolic blood pressure, serum
calcium concentration, serum magnesium concentration,
smoking, electrocardiogram Sokolow-Lyon, serum phos-
phate concentration, serum potassium concentration, total
serum protein concentration, serum sodium concentration,
serum urea concentration, total cholesterol, triglycerides,
tumor necrosis factor-alpha, uric acid, plasma viscosity, von
Willebrand factor, white cell count, waist circumference,
waist-to-hip ratio, and weight.
Additional Points
DOI. Data used in this publication are available to bona
fide researchers upon request to the NSHD Data Sharing
Committee via a standard application procedure. Further
details can be found at http://www.nshd.mrc.ac.uk/data, doi:
10.5522/NSHD/Q101. The UCLEB Consortium is composed
of the following individuals: Tina Shah, Jorgen Engmann,
Chris Finan, Amand Floriaan Schmidt, and Aroon D.
Hingorani: Institute of Cardiovascular Science, University
College London, London, United Kingdom; Caroline Dale,
Pimphen Charoen, Antoinette Amuzu, Ghazaleh Fatemifar,
Juan P. Casas, and Claudia Langenberg: Farr Institute of
Health Informatics, University College London, London,
United Kingdom; JonWhite and Vincent Plagnol: University
College London Genetics Institute, Department of Genet-
ics, Environment and Evolution, London, United Kingdom;
Frank Dudbridge: Department of Non-Communicable Dis-
ease Epidemiology, London School of Hygiene and Trop-
ical Medicine, London, United Kingdom; Meena Kumari:
Institute for Social and Economic Research, University of
Essex, Colchester, UnitedKingdom;MeenaKumari andMika
Kivimaki: Department of Epidemiology & Public Health,
UCL Institute of Epidemiology and Health Care, University
College London, London, United Kingdom; Stela McLachlan
and Jacqueline Price: Centre for Population Health Sci-
ences, University of Edinburgh, Edinburgh, United King-
dom; Christine Power and Elina Hypponen: MRC Centre of
Epidemiology for Child Health, Department of Population
Health Sciences, UCL Institute of Child Health, University
College London, London, United Kingdom; Andrew Wong,
Ken Ong, Rebecca Hardy, and Diana Kuh: MRC Unit for
Lifelong Health and Ageing, London, United Kingdom;
Ken Ong and Nicholas Wareham: MRC Epidemiology Unit,
Institute ofMetabolic Science, Addenbrooke’sHospital, Cam-
bridge, United Kingdom; Tom R. Gaunt, Debbie A. Lawlor,
George Davey Smith, and Fotios Drenos: MRC Integra-
tive Epidemiology Unit, School of Social and Community
Medicine, University of Bristol, Bristol, United Kingdom;
FotiosDrenos, JackieCooper, Philippa J. Talmud, and Steve E.
Humphries: Centre forCardiovascularGenetics, Department
of Medicine, British Heart Foundation Laboratories, Rayne
Building, Royal Free and University College Medical School,
London, United Kingdom; Reecha Sofat: Centre for Clinical
Pharmacology, University College London, London, United
Kingdom; Yoav Ben-Shlomo: School of Social and Commu-
nityMedicine, University of Bristol, Bristol, UnitedKingdom;
Peter Whincup: Population Health Research Institute, St
George’s University of London, London, United Kingdom;
Richard Morris: School of Social and Community Medicine,
University of Bristol, Bristol, United Kingdom; Barbara Jef-
feris and Goya Wanamethee: Department of Primary Care
and Population Health, UCL Institute of Epidemiology and
Health Care, University College London, London, United
Kingdom; Claudia Langenberg: MRC Epidemiology Unit,
University of Cambridge School of Clinical Medicine, Insti-
tute of Metabolic Science, Cambridge Biomedical Campus,
Cambridge, United Kingdom.
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